Axovant Gene Therapies Ltd (SIOX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Pavan Cheruvu
Employees:
57
11 TIMES SQUARE 33RD FLOOR, NEW YORK, NY 10036
877-746-4891

Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease. Sio is leveraging its foundational scientific expertise built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.

Data derived from most recent annual or quarterly report
Market Cap 19.532 Million Shares Outstanding73.705 Million Avg 30-day Volume 1.014 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.29
Price to Revenue0.0 Debt to Equity0.0 EBITDA-45.917 Million
Price to Book Value1.593 Operating Margin0.0 Enterprise Value55.404 Million
Current Ratio10.568 EPS Growth0.39 Quick Ratio9.866
1 Yr BETA 1.0323 52-week High/Low 2.95 / 0.23 Profit Margin0.0
Operating Cash Flow Growth23.3207 Altman Z-Score-2.2734 Free Cash Flow to Firm -29.128 Million
Earnings Report2022-06-09
View SEC Filings from SIOX instead.

View recent insider trading info

Axovant Gene Therapies Ltd YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding SIOX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SIOX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

NASSIF DAVID W. INTERIM CEO, CFO

  • Officer
  • Director
 546,500 2022-02-08 2

MESWANI PARAG V CHIEF COMMERCIAL OFFICER

  • Officer
 153,700 2022-02-08 2

CHERUVU PAVAN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
 278,242 2021-12-08 1

VUORI KRISTIINA MD

  • Director
 42,000 2021-04-15 0

PANDE ATUL

  • Director
 42,000 2021-04-15 0

MODIG BERNDT

  • Director
 42,000 2021-04-15 0

TORTI FRANK

  • Director
 42,000 2021-04-15 0

CORCORAN GAVIN CHIEF R&D OFFICER

  • Officer
 244,300 2021-04-15 0

SUNDARAM SENTHIL VEL

  • Director
 42,000 2021-04-15 0

ROIVANT SCIENCES LTD.

  • 10% Owner
 18,577,380 2020-02-24 0

VENKER ERIC

  • Director
 0 2020-02-17 0

VIKING GLOBAL PERFORMANCE LLC

VIKING GLOBAL EQUITIES LP

VIKING GLOBAL EQUITIES II LP

VGE III PORTFOLIO LTD.

VIKING GLOBAL EQUITIES MASTER LTD.

VIKING LONG FUND GP LLC

VIKING LONG FUND MASTER LTD.

HALVORSEN OLE ANDREAS

OTT DAVID C.

SHABET ROSE SHARON

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
 No longer subject to file 2019-07-10 0

VIKING GLOBAL INVESTORS LP

VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

VIKING GLOBAL OPPORTUNITIES GP LLC

HALVORSEN OLE ANDREAS

OTT DAVID C.

SHABET ROSE SHARON

  • 10% Owner
  • FORMER 10% OWNER FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
 No longer subject to file 2019-07-10 0

QVT ASSOCIATES GP LLC

QVT FINANCIAL INVESTMENT CAYMAN LTD.

  • 10% Owner
 No longer subject to file 2019-07-10 0

MACHADO PATRICK

  • FORMER 10% OWNER
 No longer subject to file 2019-07-10 0

DEXXON HOLDINGS LTD.

DEXCEL PHARMA TECHNOLOGIES LTD.

OREN DAN

  • SEE REMARKSSEE REMARKSSEE REMARKS
 No longer subject to file 2019-07-10 0

LO ANDREW

  • FORMER 10% OWNER
 No longer subject to file 2019-07-10 0

SVF INVESTMENTS (UK) LTD

SOFTBANK VISION FUND L.P.

SVF GP (JERSEY) LTD

SVF HOLDINGS (UK) LLP

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
 No longer subject to file 2019-07-10 0

POTTER MYRTLE S

  • Director
 0 2019-04-15 0

JEFFS ROGER

  • Director
 0 2019-04-15 0

BICKERSTAFF GEORGE

  • Director
 0 2019-04-15 0

BAZLEY MATHEW C. GENERAL COUNSEL

  • Officer
 0 2019-04-15 0

VIKING GLOBAL EQUITIES MASTER LTD.

  • 10% Owner
 99,285,714 2019-01-01 0

LOMBARDO ILISE CHIEF MEDICAL OFFICER

  • Officer
 0 2018-08-15 0

OREN ILAN

  • Director
 0 2018-06-06 0

WEINHOFF GREGORY M PRINCIPAL FINANCIAL OFFICER

  • Officer
 0 2018-03-15 0

ALTMEYER MARK PRES (ASG) & CHIEF COMM. OFC.

  • Officer
 0 2018-03-15 0

MOHR STEPHEN FREDERICK GENERAL COUNSEL

  • Officer
 0 2018-03-15 0

HUNG DAVID PRINCIPAL EXECUTIVE OFFICER

  • Officer
  • Director
 0 2017-12-29 0

DEXCEL PHARMA TECHNOLOGIES LTD.

  • 10% Owner
 75,000,000 2017-09-06 0

SHABET ROSE SHARON

  • 10% Owner
 75,000,000 2017-07-01 0

FALBERG KATHRYN E

  • Director
 0 2017-05-15 0

VERNON W ANTHONY

  • Director
 0 2017-05-15 0

FRIEDHOFF LAWRENCE MD PHD CHIEF DEVELOPMENT OFFICER

  • Officer
 0 2017-04-28 0

OLANOFF LAWRENCE S

  • Director
 0 2017-04-28 0

ADASCZIK MICHAEL PRINCIPAL ACCOUNTING OFFICER

  • Officer
 0 2017-04-28 0

PISANO GARY P.

  • Director
 0 2017-04-28 0

MCCOURT MARION PRINCIPAL OPERATING OFFICER

  • Officer
 0 2017-04-07 0

VIKING GLOBAL PERFORMANCE LLC

VIKING GLOBAL EQUITIES LP

VIKING GLOBAL EQUITIES II LP

VGE III PORTFOLIO LTD.

VIKING LONG FUND MASTER LTD.

VIKING LONG FUND GP LLC

  • 10% Owner
 75,000,000 2016-07-08 0

VIKING GLOBAL INVESTORS LP

VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

VIKING GLOBAL OPPORTUNITIES GP LLC

HALVORSEN OLE ANDREAS

OTT DAVID C.

SUNDHEIM DANIEL S.

  • 10% Owner
 75,000,000 2016-07-08 0

QVT ASSOCIATES GP LLC

QVT FUND V LP

  • 10% Owner
 75,000,000 2016-07-08 0

DEXXON HOLDINGS LTD.

OREN DAN

  • 10% Owner
 75,000,000 2016-07-08 0

CVIJIC CHRISTINE MIKAIL CHIEF ADMIN OFFICER AND GC

  • Officer
 0 2016-04-29 0

RAMASWAMY VIVEK PRINCIPAL EXECUTIVE OFFICER

  • Officer
  • Director
  • 10% Owner
 0 2016-04-29 0

ROMEO MARIANNE L. HEAD,GLOBAL TRANS & RISK MGMT

  • Officer
  • Director
 0 2016-04-29 0

ROEMER ALAN S. PRINCIPAL FIN & ACCT OFFICER

  • Officer
 0 2015-06-10 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
SIO GENE THERAPIES INC SIOX 2022-05-23 22:15:04 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 21:45:03 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 21:15:04 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 20:45:03 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 20:15:04 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 19:45:04 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 19:15:03 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 18:45:03 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 18:15:03 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 17:45:03 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 17:15:03 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 16:45:03 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 16:15:03 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 15:45:04 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 15:15:03 UTC -0.465 1.285 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 14:45:03 UTC -0.4605 1.2805 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 14:15:03 UTC -0.4605 1.2805 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 13:45:03 UTC -0.4605 1.2805 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 13:15:04 UTC -0.4605 1.2805 1900000
SIO GENE THERAPIES INC SIOX 2022-05-23 12:45:03 UTC -0.4605 1.2805 1900000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments